Health coaching startup Virta expands into prediabetes and obesity
The virtual care platform currently uses digital coaching and health monitoring to treat patients with type 2 diabetes.
Related Articles
Defiant, Pfizer CEO talks about Trump, obesity drugs, and the ‘Pfizer machine’
At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company’s obesity and oncology drugs.
Let’s talk about JPM Day 1
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Welcome, dear
‘My life’s purpose’: A neuroscientist wants to rewire mental illness treatment and remake the field he loves
Duke neuroscientist Kafui Dzirasa wants nothing less than to reengineer the brain’s electrical patterns to treat anxiety, depression, bipolar disorder, and schizophrenia.
Truveta enlists health systems, drugmakers to launch ambitious new genomic database
Health data company Truveta is partnering with health systems and drugmakers to create a massive database of genetic data from 10 million people.
STAT Madness Application
Enter to compete in this year’s STAT Madness! STAT Madness is a bracket-style tournament to find the best innovations in science and medicine from
STAT@JPM: Co-Working Space
Exclusive to STAT+ subscribers, STAT is hosting a workspace just steps from Union Square during the J.P. Morgan Healthcare Conference. Subsc…
Cytokinetics is not looking to be acquired, CEO says
The CEO of Cytokinetics says the company is not for sale. That doesn’t mean it would turn away potential suitors.
Biogen CEO confirms he’s shopping for biotechs: ‘We will be doing deals’
Biogen is looking to augment growth by hunting for biotechs with drugs in mid- and late-stage clinical development.
Cigna, Centene, Walgreens drop out of J.P. Morgan conference
Cigna and Centene were among a dozen companies that appeared on the initial JPM agenda that have bowed out of the conference.
Eli Lilly scientific chief Skovronsky says Scorpion deal ‘checked all the boxes’
Eli Lilly’s chief scientific officer said the company purchased a cancer drug from the startup Scorpion Therapeutics because it “checked all the boxes.”